PHARMING GROUP NV - ADR (PHAR) Stock Price & Overview
NASDAQ:PHAR • US71716E1055
Current stock price
The current stock price of PHAR is 16.68 USD. Today PHAR is up by 0.24%. In the past month the price increased by 2.27%. In the past year, price increased by 96%.
PHAR Key Statistics
- Market Cap
- 1.178B
- P/E
- 834.00
- Fwd P/E
- 47.38
- EPS (TTM)
- 0.02
- Dividend Yield
- N/A
PHAR Stock Performance
PHAR Stock Chart
PHAR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to PHAR. When comparing the yearly performance of all stocks, PHAR is one of the better performing stocks in the market, outperforming 87.35% of all stocks.
PHAR Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to PHAR. While PHAR has a great health rating, its profitability is only average at the moment.
PHAR Earnings
On March 12, 2026 PHAR reported an EPS of 0.08 and a revenue of 106.53M. The company missed EPS expectations (-6.76% surprise) and missed revenue expectations (-1.68% surprise).
PHAR Forecast & Estimates
14 analysts have analysed PHAR and the average price target is 25.84 USD. This implies a price increase of 54.94% is expected in the next year compared to the current price of 16.68.
For the next year, analysts expect an EPS growth of 1671.6% and a revenue growth 8.86% for PHAR
PHAR Groups
Sector & Classification
PHAR Financial Highlights
Over the last trailing twelve months PHAR reported a non-GAAP Earnings per Share(EPS) of 0.02. The EPS increased by 111.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.76% | ||
| ROA | 0.57% | ||
| ROE | 1.03% | ||
| Debt/Equity | 0.39 |
PHAR Ownership
PHAR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.09 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.44 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.23 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PHAR
Company Profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Info
IPO: 1998-07-02
PHARMING GROUP NV - ADR
Darwinweg 24
Leiden ZUID-HOLLAND 2333 CR NL
CEO: Sijmen de Vries
Employees: 407
Phone: 31715247400
PHARMING GROUP NV - ADR / PHAR FAQ
Can you describe the business of PHARMING GROUP NV - ADR?
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Can you provide the latest stock price for PHARMING GROUP NV - ADR?
The current stock price of PHAR is 16.68 USD. The price increased by 0.24% in the last trading session.
Does PHAR stock pay dividends?
PHAR does not pay a dividend.
What is the ChartMill rating of PHARMING GROUP NV - ADR stock?
PHAR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is PHARMING GROUP NV - ADR (PHAR) stock traded?
PHAR stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of PHAR stock?
PHARMING GROUP NV - ADR (PHAR) operates in the Health Care sector and the Biotechnology industry.
Would investing in PHARMING GROUP NV - ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PHAR.